asthma
Respiratory · 2007–2025
44decisions
22medicines
26carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dupilumab Treatment of chronic severe atopic dermatitis in paediatric patients aged less than 12 years, and uncontrolled severe asthma in paediatric patients aged 6 to… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| omalizumab Treatment of uncontrolled severe asthma (USA) in patients aged 12 years or older, uncontrolled severe allergic asthma (USAA) in patients aged 6 to 12 years,… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy · Asthma Australia · National Allergy Council · Anaphylaxis Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Maintenance and reliever treatment (MART) for asthma in adults aged 18 years or older who experience frequent asthma symptoms while receiving treatment with a… | Mar 2024 | Recommended with restriction | input received Asthma Australia · National Asthma Council Australia |
| dupilumab Treatment of patients aged 6 to 11 years with uncontrolled severe asthma who have total serum IgE ≥ 30 IU/mL and evidence of atopy, or blood eosinophils ≥ 150… | Mar 2024 | Recommended with restriction | input received Asthma Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council · Anaphylaxis Australia |
| mepolizumab Treatment of uncontrolled severe asthma in patients aged 12 years and over. | Mar 2024 | Not recommended | 1 individuals Australasian Society of Clinical Immunology and Allergy · National Allergy Council · Anaphylaxis Australia · Medical Research Council · Asthma Australia |
| tiotropium Treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and for the treatment of severe asthma in adults and… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| budesonide with formoterol Treatment of asthma in adults and adolescents aged 12 years and older, and symptomatic treatment of moderate to severe COPD in adults with FEV1 ≤50% predicted… | Nov 2023 | Recommended with restriction | input received Asthma Australia · Both Asthma Australia · Lung Foundation Australia |
| fluticasone propionate with salmeterol Treatment of asthma in patients aged 4 years or older (250/50 and 500/50 strengths), and symptomatic treatment of severe COPD in patients with a history of… | Nov 2023 | Recommended with restriction | input received Asthma Australia · Both Asthma Australia · Lung Foundation Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Maintenance treatment of asthma in adults (18 years and older) not adequately controlled with inhaled corticosteroids and 'as needed' rapid-acting… | Jul 2022 | Recommended with restriction | input received Asthma Australia |
| beclometasone with formoterol and glycopyrronium Maintenance therapy of severe asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta-2 agonist and an inhaled… | Mar 2022 | Deferred | input received Asthma Australia |
| dupilumab Chronic severe atopic dermatitis and uncontrolled severe asthma in patients aged 12 years and older (autoinjector form); the pre-filled syringe form is… | Nov 2022 | Recommended | input received Asthma Australia |
| fluticasone furoate / umeclidinium / vilanterol Maintenance therapy of severe asthma in adults who are not adequately controlled with a combination of inhaled corticosteroid and long-acting beta2-agonist,… | Nov 2021 | Recommended with restriction | input received |
| omalizumab Uncontrolled severe allergic asthma (USAA) in children aged 6 to less than 12 years, and uncontrolled severe asthma in adults and adolescents aged 12 years and… | Nov 2021 | Not recommended | input received Asthma Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Maintenance treatment of asthma in adults aged 18 years or older; patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled… | Jul 2020 | Recommended with restriction | input received National Asthma Council · Asthma Australia |
| mometasone furoate / indacaterol / glycopyrronium Maintenance therapy of severe asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled… | Jul 2020 | Deferred | input received Asthma Australia |
| mometasone furoate with indacaterol Maintenance treatment of asthma in patients aged 12 years or over who have previously had frequent episodes of asthma while receiving treatment with oral… | Jul 2020 | Recommended with restriction | input received Asthma Australia |
| tiotropium Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in adults and children aged 6–17 years. | Jul 2020 | Recommended | 1 individuals Lung Foundation · Asthma Australia |
| salbutamol Pressurised inhalation formulation with integrated dose counter for acute bronchospasm relief and asthma management. The submission concerns a reformulation of… | Mar 2020 | Recommended with restriction | no section in document |
| budesonide with formoterol Extension of listing for use as an anti-inflammatory reliever therapy administered as needed for adolescent and adult patients with mild asthma who are… | Jul 2019 | Not recommended | 1 individuals Asthma Australia |
| fluticasone furoate Maintenance treatment of asthma in children aged 5 to 11 years. | Jul 2019 | Recommended with restriction | input received |
| budesonide + formoterol Asthma in children aged <12 years who have failed PBS-subsidised fluticasone propionate and salmeterol as a fixed dose combination. | Dec 2019 | Recommended with restriction | no section in document |
| budesonide with formoterol Mild asthma in adolescent and adult patients for use as an anti-inflammatory reliever therapy administered as needed. | Nov 2019 | Recommended with restriction | 2 individuals Asthma Australia · Lung Foundation |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults with frequent episodes or symptoms despite corticosteroid or ICS/LABA therapy, and treatment of COPD in adults with FEV1 <50%… | Aug 2018 | Recommended with restriction | none received |
| tiotropium Severe asthma in children aged 6 to 17 years who remain uncontrolled despite receiving optimised asthma therapy (high-dose inhaled corticosteroid plus… | Mar 2018 | Not recommended | input received Asthma Australia |
| fluticasone propionate with formoterol fumarate dihydrate Regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2-agonist) is appropriate,… | Nov 2018 | Not recommended | none received |
| tiotropium Add-on maintenance bronchodilator treatment for children and adolescents aged 6-17 years with severe asthma who have not achieved adequate asthma control… | Nov 2018 | Recommended with restriction | input received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients aged 18 years and over. | Jul 2017 | Not recommended | input received |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with severe asthma who are currently treated with maintenance combination of inhaled… | Jul 2017 | Not recommended | none received |
| fluticasone furoate Maintenance treatment of asthma in patients aged ≥12 years. | Mar 2017 | Noted | none received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults aged 18 years and over with frequent asthma episodes or symptoms despite oral/inhaled corticosteroid therapy, or those requiring… | Nov 2017 | Recommended | none received |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with severe asthma who are currently treated with inhaled corticosteroids (≥800 microgram… | Nov 2017 | Not recommended | no section in document |
| tiotropium Add-on maintenance bronchodilator treatment in adult patients with asthma currently treated with inhaled corticosteroids and long-acting beta-2 agonists who… | Mar 2016 | Recommended with restriction | input received National Asthma Council Australia |
| fluticasone propionate with salmeterol xinafoate Treatment of asthma in adults with frequent episodes while receiving oral corticosteroids or optimal doses of inhaled corticosteroids, and symptomatic… | Nov 2016 | Not recommended | input received Thoracic Society of Australia · National Asthma Council Australia · Asthma Australia |
| salbutamol Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients unable to use salbutamol delivered from an oral pressurised inhalation device… | Nov 2016 | Recommended | none received |
| tiotropium bromide Add-on maintenance bronchodilator treatment in adult patients with severe persistent asthma who are currently treated with the maintenance combination of… | Jul 2015 | Not recommended | input received Lung Foundation |
| fluticasone furoate Maintenance treatment of asthma in patients aged 12 years and over. | Nov 2015 | Recommended | none received |
| fluticasone furoate and vilanterol trifenatate Regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long acting beta-2 agonist and inhaled… | Mar 2014 | Recommended with restriction | unclear |
| salbutamol Relief of bronchospasm in patients with obstructive airway disease. This submission concerns a new pack size (128 capsules) to replace the existing 100 capsule… | Nov 2014 | Recommended | no section in document |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma (maintenance and SMART regimen) and chronic obstructive pulmonary disease (COPD) in adults and adolescents. | Jul 2013 | Recommended | no section in document |
| fluticasone propionate with eformoterol fumarate Regular maintenance treatment of asthma in patients who require combination therapy with an inhaled corticosteroid and a long-acting beta-2 agonist. | Jul 2013 | Recommended with restriction | no section in document |
| salbutamol sulfate Relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other… | Mar 2010 | Not recommended | no section in document |
| montelukast sodium Prevention of exercise-induced asthma in children aged 6 to 14 years whose asthma is otherwise well controlled while receiving optimal dose inhaled… | Jul 2009 | Recommended with restriction | no section in document |
| budesonide with eformoterol fumarate dihydrate Extension of listing to include initiation of single maintenance and reliever therapy in patients who experience frequent asthma symptoms while receiving… | Mar 2007 | Recommended with restriction | no section in document |
| Budesonide with Eformoterol Fumarate Dihydrate Extension of listing to include initiation of single maintenance and reliever therapy in patients who experience frequent asthma symptoms while receiving… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Asthma Australia · Australasian Society of Clinical Immunology and Allergy · National Allergy Council · Anaphylaxis Australia · National Asthma Council Australia · Lung Foundation · Lung Foundation Australia · Both Asthma Australia · National Asthma Council · Thoracic Society of Australia · Medical Research Council
What the PBS pays
$2,825M in government benefit over 2024–25, across 52,534,961 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| dupilumab | $490.8M |
| fluticasone propionate with formoterol fumarate dihydrate | $322.7M |
| fluticasone furoate / umeclidinium / vilanterol | $218.9M |
| fluticasone furoate | $200.3M |
| fluticasone furoate / vilanterol trifenatate | $200.3M |
| fluticasone propionate with eformoterol fumarate | $200.3M |
| budesonide + formoterol | $144.7M |
| budesonide with formoterol | $144.7M |
| beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium | $137.2M |
| beclometasone dipropionate with formoterol fumarate dihydrate | $126.6M |
| beclometasone with formoterol | $126.6M |
| budesonide with eformoterol fumarate dihydrate | $102.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tezepelumabTezepelumab for treating severe asthma | TA880 | recommended restricted | 2023-04 |
| dupilumabDupilumab for treating severe asthma with type 2 inflammation | TA751 | recommended restricted | 2021-12 |
| omalizumabOmalizumab for treating severe persistent allergic asthma | TA278 | recommended restricted | 2013-04 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| ipratropium bromideAERON 250 ipratropium bromide (as monohydrate) 250 microgram/mL inhal | 1991 | 10 |
| ephedrineDBL EPHEDRINE SULFATE 30mg/1mL Injection | 1991 | 8 |
| american house dust mite extract + european house dust mite extractACARIZAX (American house dust mite extract and European house dust mit | 2006 | 5 |
| theophyllineNEULIN SR 200 theophylline 200mg tablet bottle | 1993 | 3 |
| ethylenediamine + theophyllineDBL AMINOPHYLLINE 250mg/10mL injection ampoule | 1991 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 26 of 38 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.